Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Yueyang Central Hospital | China

AUTHOR PROFILE

ORCID ID

📚EARLY ACADEMIC PURSUITS 

ZENG QINGJUN completed his Master’s degree at Xiangya Medical College, Central South University, in 2010. This prestigious institution provided a strong foundation in medical education, equipping him with the skills and knowledge necessary for his future in the field of gastrointestinal surgery. His academic training allowed him to develop expertise in complex surgical techniques, laying the groundwork for his career as a clinical specialist in surgery.

⚕️PROFESSIONAL ENDEAVORS 

Since July 2010, ZENG QINGJUN has been working in the field of gastrointestinal surgery, focusing on laparoscopic techniques for treating gastric and colorectal cancers. As a chief physician, he plays a pivotal role in leading surgical teams, performing high-risk surgeries, and making critical decisions for patient care. His clinical expertise and skillful handling of over 200 laparoscopic gastric cancer surgeries and 400 laparoscopic colorectal cancer surgeries are testaments to his proficiency in minimally invasive surgical methods. His surgical outcomes have contributed significantly to improving the quality of life for cancer patients and are recognized within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON GASTROINTESTINAL TUMORS

Dr. ZENG has dedicated much of his professional life to the development and refinement of laparoscopic surgical techniques in the treatment of gastrointestinal cancers. His research is heavily focused on advancing minimally invasive surgery, particularly in the areas of gastric cancer and colorectal cancer. Through clinical trials and innovative methodologies, he has been involved in optimizing surgical procedures to ensure better postoperative recovery, reduced complications, and more efficient treatment pathways for cancer patients.

🌍IMPACT AND INFLUENCE 

Dr. ZENG QINGJUN has made an immense impact on the practice of gastrointestinal surgery in China, particularly in the realm of laparoscopic surgery. His innovative approaches and commitment to cutting-edge techniques have influenced both local and national surgical practices. His contribution to gastric and colorectal cancer surgery has improved patient outcomes and has set new standards in the field. As a chief physician, he mentors younger surgeons and shares his expertise, ensuring the continued progress of surgical techniques.

📑ACADEMIC CITATIONS 

While detailed citation metrics are not provided, Dr. ZENG’s extensive clinical experience and research endeavors have led to his recognition in academic circles. His focus on laparoscopic techniques and cancer surgery continues to influence current and future generations of surgeons and researchers in the field. His work, particularly in gastric and colorectal cancer, has made notable contributions to medical literature and has been referenced in various academic and clinical studies.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Dr. ZENG QINGJUN’s career reflects a legacy of excellence in surgical practice and medical innovation. His pioneering work in laparoscopic surgery and cancer treatment has already set the stage for future breakthroughs in the field of gastrointestinal oncology. Looking forward, he is likely to contribute even more significantly to surgical research, possibly expanding his focus to robot-assisted surgeries, postoperative care advancements, and the integration of AI in surgical planning. His mentorship, both locally and nationally, will shape the future of surgical education and the next generation of gastrointestinal surgeons.

💼LEADERSHIP IN SURGICAL PRACTICE 

Dr. ZENG continues to hold a significant leadership role in the surgical department at his medical institution. His capacity as chief physician enables him to make high-level decisions in clinical practice, direct surgical teams, and implement best practice guidelines. His strategic leadership in gastrointestinal surgery helps to establish protocols for laparoscopic surgeries, improving surgical outcomes, and pushing the boundaries of traditional approaches.

🔗 CONCLUSION

Dr. Zeng Qingjun is a distinguished gastrointestinal surgeon whose work has significantly advanced the field of laparoscopic surgery for gastric and colorectal cancers. With over a decade of experience and hundreds of successful surgeries, his contributions have set new standards in minimally invasive surgical techniques, improving patient outcomes and recovery times. Through his leadership as chief physician, he has not only influenced clinical practices but has also become a mentor to aspiring surgeons, ensuring the continuity of high-quality surgical education.

📊🔬NOTABLE PUBLICATION:
  • 1. Title: Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway
    Authors: Qingjun Zeng, Sanjun Zhang, Linfang He, Qingyan Fu, Li Liao, Linjie Chen, Xiang Ding
    Journal: Cancer Biotherapy and Radiopharmaceuticals
    Year: 2023


    2. Title: Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells
    Authors: Xiang Ding, Qingyan Fu, Weixing Chen, Linjie Chen, Qingjun Zeng, Sanjun Zhang, Linfang He
    Journal: Cell Biology International
    Year: 2022

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Ms. Xin Xin | Cancer Biomarkers | Best Researcher Award

Shanghai University of Traditional Chinese Medicine | China

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS

Xin Xin’s academic journey is rooted in the integration of Traditional Chinese Medicine (TCM) with Western medicine, particularly focusing on reproductive health and gynecology. He obtained a Bachelor of Science in Chinese Medicine from Shandong University of Traditional Chinese Medicine. His academic foundation continued to expand as he pursued an MD in Gynecology of Traditional Chinese Medicine, further honing his expertise in reproductive diseases. Xin is currently working towards his PhD in Clinical Chinese Medicine Integrated with Western Medicine at Shanghai University of Traditional Chinese Medicine, under the guidance of Advisor Jinfu Zhang.

💼 PROFESSIONAL ENDEAVORS

Xin Xin’s professional career is centered on bridging the gap between traditional and modern medical approaches. He is particularly involved in the clinical and mechanistic research of reproductive diseases, with a primary focus on polycystic ovary syndrome (PCOS). His work aims to enhance diagnostic methods and treatment approaches through a combined understanding of TCM and Western medicine. Xin has contributed significantly to clinical studies and investigations, with his academic path guided by prominent scholars in the field, including Dr. Fang Lian and Dr. Haicui Wu during his MD program at Shandong University.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Xin Xin’s research is notable for its emphasis on the pathogenesis, diagnosis, and treatment of reproductive diseases, with a particular focus on PCOS. He has undertaken several groundbreaking projects, one of which explores the expression of long non-coding RNAs (lncRNA) in follicular fluid exosomes of patients with obesity and PCOS using high-throughput sequencing technology. This research represents an effort to better understand the molecular mechanisms behind PCOS and to uncover novel biomarkers for early detection and intervention.

Another area of Xin’s research explores the role of Bone Morphogenetic Protein 6 (BMP6) in regulating Pentraxin 3 expression in human granulosa lutein cells in women with PCOS. His studies are pivotal in uncovering molecular markers and pathways that could lead to more effective therapeutic strategies.

🌟 IMPACT AND INFLUENCE

Xin Xin’s work has garnered attention within the scientific community due to his innovative approach of combining traditional Chinese medicine with Western medical techniques. His research aims to contribute to the development of a more holistic and comprehensive understanding of reproductive diseases. By investigating both the molecular and clinical aspects of PCOS, Xin is pushing boundaries in reproductive health research. His work has the potential to change how clinicians approach the treatment of polycystic ovary syndrome, a condition that affects millions of women worldwide.

📑 ACADEMIC CITES

Although his research is relatively recent, Xin Xin’s work is beginning to attract attention in the academic community. His publications on the expression of lncRNAs and BMP6 in PCOS are contributing to the growing body of knowledge on this common reproductive disorder. These publications are expected to increase in citations as they influence future studies and clinical approaches. His articles, including “Exploring lncRNA expression in follicular fluid exosomes of patients with obesity and polycystic ovary syndrome” (2024), and “Bone Morphogenetic Protein 6 Induces Downregulation of Pentraxin 3 Expression in Human Granulosa Lutein Cells in Women With Polycystic Ovary Syndrome” (2024), are already making a mark in reproductive health research.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Xin Xin is poised to continue his impactful contributions to the field of reproductive medicine. With a focus on integrating TCM with Western medical practices, his future research may lead to the development of novel therapeutic modalities for PCOS and other reproductive diseases. He is likely to remain an influential figure in the field of gynecology, particularly in areas that explore the intersections between traditional and modern approaches to healthcare. His research has the potential to influence both clinical practices and medical education, paving the way for new, more integrated methods of treating complex reproductive health conditions.

In the coming years, Xin Xin’s work will likely expand into further clinical trials and studies, contributing to the refinement of treatments for women with PCOS, and potentially providing a more personalized and effective approach to reproductive medicine globally.

✨Conclusion:

Xin Xin’s academic and professional journey stands as a testament to the growing importance of integrating traditional and modern medical practices in addressing complex health conditions. His dedicated research in reproductive medicine, particularly focusing on polycystic ovary syndrome (PCOS), has already made valuable contributions to understanding its pathogenesis and improving diagnostic and therapeutic methods. By exploring innovative molecular mechanisms and combining high-throughput sequencing technology with traditional Chinese medicine, Xin is laying the groundwork for a more holistic approach to treating reproductive diseases.

📊🔬NOTABLE PUBLICATION:
  • Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching
    • Authors: Dong, L., Lian, F., Wu, H., Yu, X., Xin, X.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2022

 

  • The effect of large follicle puncture and aspiration on the outcomes of IVF-ET in patients with asynchronized follicles under the long GnRH-a protocol: a retrospective cohort study
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: BMC Pregnancy and Childbirth
    • Year: 2023

 

  • Effect of human chorionic gonadotropin injection before frozen-thawed embryo transfer: A retrospective cohort study
    • Authors: Xin, X., Dong, L., Guan, L., Li, J., Lian, F.
    • Journal: Medicine (United States)
    • Year: 2023

 

  • Clinical Efficacy and Mechanism of Erzhi Tiangui Prescription in Treatment of Patients with Repeated Implantation Failure of Kidney Deficiency Syndrome Based on sPD-1 and Th17/Treg Cytokines
    • Authors: Wang, Y., Pang, C., Wu, H., Xin, X., Lian, F.
    • Journal: Chinese Journal of Experimental Traditional Medical Formulae
    • Year: 2023

 

  • Total knee arthroplasty in patients with Klippel Trenaunay syndrome and knee osteoarthritis: A case report and a literature review
    • Authors: Li, J., Lv, G., Han, Z., Xin, X.
    • Journal: Medicine (United States)
    • Year: 2024

Dr. Lei Xia | Theranostics | Best Researcher Award

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
📞 Phone: 18811177191
✉️ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes 🧪
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

📊🔬Notable Publication:

 

 

 

 

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

 

Prof. Paolo De Simone – Oncology Therapy – Most Liked Article Award

Prof. Paolo De Simone - Oncology Therapy - Most Liked Article Award

UNIVERSITY OF PISA - Italy

Author Profile

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Paolo De Simone graduated summa cum laude in Medicine and Surgery from the University of Rome La Sapienza. His thesis was titled "Laparoscopic cholecystectomy in the treatment of gallstone lithiasis: prospective analysis of the results of our experience" under the supervision of Prof. Raffaello Cortesini.He earned his Specialist Diploma in General Surgery summa cum laude from the University of Rome “La Sapienza”. His thesis focused on "The role of laparoscopic surgery in the treatment of benign and malignant gastric pathologies" under the guidance of Prof. Raffaello Cortesini.Paolo De Simone achieved his PhD summa cum laude in Surgical Pathophysiology.

PROFESSIONAL ENDEAVORS

Registered in the Order of Doctors-Surgeons and Dentists of the Province of Rome with registration number 46702. He also qualified to practice the medical-surgical profession at the University of Rome “La Sapienza”. He served as a Foreign Resident-Assistant at the General Surgery Service of CHU André Vésale, Université Libre de Bruxelles, Montigny-Le-Tilleul, Belgium, and at the Thoracic and Vascular Surgery Service of the Hospital Avicenne, Bobigny, France. Paolo De Simone held several medical director positions:General Surgery Unit, Civil Hospital of Vittorio Veneto (TV),Organ Transplant Unit, San Salvatore Civil Hospital, L'Aquila,Service de Chirurgie Digestive, Hopital Erasme, Université Libre de Bruxelles, Brussels,University Liver Transplantology Unit, Pisa University Hospital.Currently, he is an Associate Professor of Surgery at the University of Pisa. He was elected Director of the School of Specialization in Surgery of the Digestive System and serves as Director of the Liver Surgery and Liver Transplant Unit, AOUP.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY THERAPY

Appointed as the Coordinator of the regional liver transplant program by DGRT of 17 December 2018, n. 1450. He also managed clinical, scientific, and educational coordination of terminal liver failure and liver transplantation (DG AOUP Resolution 852 of 09/20/2023).His research has covered areas like laparoscopic cholecystectomy, treatment of benign and malignant gastric pathologies, and liver transplantology.

IMPACT AND INFLUENCE

As Coordinator of the Liver Transplant Program of the Tuscany Region, he has significantly contributed to the advancement of liver transplantation in the region.

LEGACY AND FUTURE CONTRIBUTIONS

Paolo De Simone's legacy lies in his extensive contributions to the fields of general surgery, liver surgery, and liver transplantology. His future contributions are anticipated in enhancing liver transplant programs, furthering research in surgical pathophysiology, and mentoring the next generation of surgeons through his academic roles.

NOTABLE PUBLICATIONS

Everolimus Mitigates the Risk of Hepatocellular Carcinoma Recurrence after Liver Transplantation.

First-in-human liver transplantation from a centenarian deceased donor after brain death.

Aging with a Liver Graft: Analysis of Very Long-Term Survivors after Liver Transplantation.

An Unexpected Case of Opisthorchis felineus Infection Revealed during Liver Transplantation.

An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients.